Epirus Biopharmaceuticals is a Boston-based biopharmaceutical company developing biosimilar monoclonal antibodies, focused on global development and commercialization. Its pipeline includes BOW015 (a biosimilar to Remicade®), BOW050 (a biosimilar to Humira®) and BOW030 (a biosimilar to Avastin®). The company has reported positive Phase 1 and Phase 3 data for BOW015; the Phase 3 trial met its predefined endpoint and demonstrated comparable efficacy, safety and immunogenicity to Remicade® as measured by ACR20 in severe rheumatoid arthritis patients. Epirus closed a $36 million Series B financing to support commercialization and further clinical development of BOW015 and ongoing pipeline activities. The company plans to initiate an additional Phase 3 trial for BOW015 in Europe in early 2015. Epirus pursues a market-specific commercialization strategy—partnering with local companies in emerging markets, using its SCALE™ platform with local partners for in-market manufacturing in select high-growth markets, and combining direct sales with local distributors in established markets such as Europe.

Total raised

$36M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2014